Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients
- PMID: 34632574
- DOI: 10.1111/bjd.20805
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients
Abstract
Background: A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome ('Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome').
Objectives: To describe clinical characteristics, laboratory findings and outcomes of VEXAS syndrome.
Methods: One hundred and sixteen patients with VEXAS syndrome were referred to a French multicentre registry between November 2020 and May 2021. The frequency and median of parameters and vital status, from diagnosis to the end of the follow-up, were recorded.
Results: The main clinical features of VEXAS syndrome were found to be skin lesions (83%), noninfectious fever (64%), weight loss (62%), lung involvement (50%), ocular symptoms (39%), relapsing chondritis (36%), venous thrombosis (35%), lymph nodes (34%) and arthralgia (27%). Haematological disease was present in 58 cases (50%): myelodysplastic syndrome (MDS; n = 58) and monoclonal gammopathy of unknown significance (n = 12; all patients with MGUS also have a MDS). UBA1 mutations included p.M41T (45%), p.M41V (30%), p.M41L (18%) and splice mutations (7%). After a median follow-up of 3 years, 18 patients died (15·5%; nine of infection and three due to MDS progression). Unsupervised analysis identified three clusters: cluster 1 (47%; mild-to-moderate disease); cluster 2 (16%; underlying MDS and higher mortality rates); and cluster 3 (37%; constitutional manifestations, higher C-reactive protein levels and less frequent chondritis). The 5-year probability of survival was 84·2% in cluster 1, 50·5% in cluster 2 and 89·6% in cluster 3. The UBA1 p.Met41Leu mutation was associated with a better prognosis.
Conclusions: VEXAS syndrome has a large spectrum of organ manifestations and shows different clinical and prognostic profiles. It also raises a potential impact of the identified UBA1 mutation.
© 2021 British Association of Dermatologists.
Comment in
-
Working towards a better understanding of VEXAS syndrome.Br J Dermatol. 2022 Mar;186(3):392-393. doi: 10.1111/bjd.20949. Epub 2022 Mar 1. Br J Dermatol. 2022. PMID: 35230698 No abstract available.
Similar articles
-
VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort.Rheumatology (Oxford). 2025 Jun 1;64(6):3747-3755. doi: 10.1093/rheumatology/keaf094. Rheumatology (Oxford). 2025. PMID: 39937690
-
Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.Arthritis Rheumatol. 2021 Oct;73(10):1886-1895. doi: 10.1002/art.41743. Epub 2021 Aug 31. Arthritis Rheumatol. 2021. PMID: 33779074
-
VEXAS Syndrome.2025 May 15. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2025 May 15. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 40373178 Free Books & Documents. Review.
-
VEXAS syndrome with progression of MDS to MDS/MPN overlap syndrome.BMJ Case Rep. 2022 Dec 22;15(12):e251089. doi: 10.1136/bcr-2022-251089. BMJ Case Rep. 2022. PMID: 36549759 Free PMC article.
-
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.Clin Rheumatol. 2022 Nov;41(11):3565-3572. doi: 10.1007/s10067-022-06338-1. Epub 2022 Aug 20. Clin Rheumatol. 2022. PMID: 35986821 Review.
Cited by
-
The First Korean Case of VEXAS Syndrome Caused by a UBA1 Somatic Variant.Ann Lab Med. 2023 Mar 1;43(2):217-220. doi: 10.3343/alm.2023.43.2.217. Epub 2022 Oct 25. Ann Lab Med. 2023. PMID: 36281520 Free PMC article. No abstract available.
-
Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome.Blood Adv. 2023 Dec 26;7(24):7445-7456. doi: 10.1182/bloodadvances.2023010531. Blood Adv. 2023. PMID: 38091008 Free PMC article.
-
Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients.RMD Open. 2022 Jul;8(2):e002255. doi: 10.1136/rmdopen-2022-002255. RMD Open. 2022. PMID: 35868738 Free PMC article.
-
Spectrum of clonal hematopoiesis in VEXAS syndrome.Blood. 2023 Jul 20;142(3):244-259. doi: 10.1182/blood.2022018774. Blood. 2023. PMID: 37084382 Free PMC article.
-
Kidney involvement in VEXAS syndrome: insights from a rare case of secondary amyloidosis and systematic review of renal biopsy-confirmed reports.Clin Rheumatol. 2025 Jul;44(7):3101-3108. doi: 10.1007/s10067-025-07506-9. Epub 2025 May 30. Clin Rheumatol. 2025. PMID: 40445522 Free PMC article. Review.
References
-
- Beck DB, Ferrada MA, Sikora KA et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2020; 383:2628-38.
-
- van der Made CI, Potjewijd J, Hoogstins A et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of VEXAS patients. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2021.05.014.
-
- Ferrada MA, Sikora KA, Luo Y et al. Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS syndrome. Arthritis Rheumatol 2021; 73:1886-95.
-
- Tsuchida N, Kunishita Y, Uchiyama Y et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220090.
-
- Bourbon E, Heiblig M, Gerfaud-Valentin M et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood 2021; 137:3682-4.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous